Skip to Main Content
Table 1—

Adherence to national guidelines for prevention of diabetic nephropathy in Finland

NormoalbuminuriaMicroalbuminuriaOvert nephropathyEnd-stage renal disease*Not classifiableAll
n 1,422 366 482 271 574 3,115 
Good glycemic control 28 18 12 23 29 24 
Current smokers 22 30§ 29§ 18 26§ 24 
Untreated hypertension 17 12 3 7 11§ 12 
Antihypertensive therapy 15 66 95 90 27 42 
Controlled hypertension# 22 33 19 8 26 21 
ACE inhibitor/angiotensin receptor blocker** 65/12 81/12 78/12 23/5 71/18 66/11 
NormoalbuminuriaMicroalbuminuriaOvert nephropathyEnd-stage renal disease*Not classifiableAll
n 1,422 366 482 271 574 3,115 
Good glycemic control 28 18 12 23 29 24 
Current smokers 22 30§ 29§ 18 26§ 24 
Untreated hypertension 17 12 3 7 11§ 12 
Antihypertensive therapy 15 66 95 90 27 42 
Controlled hypertension# 22 33 19 8 26 21 
ACE inhibitor/angiotensin receptor blocker** 65/12 81/12 78/12 23/5 71/18 66/11 

Data are percentages.

*

Kidney transplant (n = 202) and dialysis (n = 69);

HbA1c <7.5%;

P < 0.001 vs. normoalbuminuric patients;

§

P < 0.01 vs. normoalbuminuric patients;

blood pressure >140/90 mmHg, no antihypertensive treatment;

P < 0.05 vs. normoalbuminuric patients;

#

antihypertensive treatment, blood pressure <130/85 mmHg;

**

the proportion of patients on antihypertensive therapy receiving ACE inhibitors or angiotensin receptor blockers.

Close Modal

or Create an Account

Close Modal
Close Modal